MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)


The Company is relying on the U.S. Securities and Exchange CommissionMarch 25,
2020
Order Pursuant to Section 36 of the Exchange Act (Release No. 34-88465
(“Order”) in delaying the filing of this Quarterly Report for the three months
ended March 31, 2020 due to circumstances related to the COVID-19 pandemic. In
particular, COVID-19 has caused limited access to the Company’s facilities and
disrupted normal interactions with its accounting personnel, auditors and others
involved in the preparation of this Quarterly Report. The filing of this
Quarterly Report on the date hereof will be considered a timely filing under the
Order.

The information and financial data discussed below is derived from the unaudited
condensed consolidated interim financial statements of the Target Group Inc.
(“we,” “us” or the “Company”) for the three months ended March 31, 2020 and were
prepared and presented in accordance with generally accepted accounting
principles in the United States.



Forward Looking Statements


Some of the statements contained in this Quarterly Report on Form 10-Q that are
not historical facts are “forward -looking statements” which can be identified
by the use of the terminology such as “estimates,” “projects,” “plans,”
“believes,” “expects,” “anticipates,” “intends,” or the negative or other
variations, or by discussions of strategy that involve risks and uncertainties.
We urge you to be cautious of the forward-looking statements, that such
statements, which are contained in this Quarterly Report, reflect our current
beliefs with respect to future events and involve known and unknown risks,
uncertainties and other factors affecting our operations, market growth,
services, products and licenses. No assurances can be given regarding the
achievement of future results, as actual results may differ materially as a
result of the risks we face, and actual events may differ from the assumptions
underlying the statements that have been made regarding anticipated events.
Factors that may cause actual results, our performance or achievements to differ
materially from those contemplated by such forward-looking statements include
without limitation:

· Our ability to raise capital when needed and on acceptable terms and

  conditions;



· Our ability to attract and retain management;

· Our ability to enter in to long-term supply agreements for the mineralized

  material;



· General economic conditions; and

· Other factors discussed in Risk Factors.

All forward-looking statements made in connection with this Quarterly Report
that are attributable to us or persons acting on our behalf are expressly
qualified in their entirety by these cautionary statements. Given the
uncertainties that surround such statements you are cautioned not to place undue
reliance on such forward-looking statements.



Overview


Target Group Inc. (“Target Group” or “the Company”) was incorporated in the
State of Delaware on July 2, 2013, under our original name of River Run
Acquisition Corporation
. On May 5, 2014, we issued 500,000 shares of common
stock to Rubin Schindermann and 500,000 shares of Common Stock to Alexander
Starr
. With the issuance of these shares and the redemption of 19,500,000 shares
of common stock issued to our original officers, directors and shareholders, we
effected a change of control. Mr. Schindermann and Mr. Starr became our new
officers and directors. They accepted the resignations of our original founding
officers and directors. Effective May 13, 2014, the Company changed its name to
Chess Supersite Corporation.

On July 23, 2014, we acquired certain assets (“Acquisition”) of Chess Supersite,
Inc.
, a corporation existing under the laws of Ontario, Canada (“Chess Canada”).
The Acquisition was consummated pursuant to the terms of the Asset Purchase
Agreement and the issuance of 5,000,000 shares of our common stock to Chess
Canada
. In the Acquisition, we acquired all right, title and interest in and to
the properties, assets, interests and rights of Chess Canada, including the
contracts and intellectual property which are related to the business of
developing, operating and maintaining a website focused on the game of chess.
Chess Supersite, Inc. is under the common control of Rubin Schindermann and Alexander Starr.

Our original business comprised the operation of an extensive chess gaming
website under the name ChessStars™. This comprehensive user-friendly web site
www.chessstars.com, offered a state-of-the-art playing zone, broadcasts of the
major tournaments, intuitive mega database, chess skilled contests and much
more.

On July 3, 2018, we filed an amendment in our Certificate of Incorporation to
change our name to Target Group Inc. Effective October 18, 2018, our common
stock became eligible for quotation on the OTCQB platform operated by OTC
Markets Group Inc, under the symbol “CBDY”.

Effective December 12, 2018, our Board of Directors approved the termination of
our ChessStars™ online chess playing platform effective December 31, 2018. We
will seek to sell all of the assets that comprise the ChessStars™ business. to a
third-party buyer at the best possible price.



  5





ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (continued)

Business and Plan of Operations



Cannabis Business-Canada


We are now engaged in the cultivation, processing and distribution of curated
cannabis products for the adult-use medical and recreational cannabis market in
Canada and, where legalized by state legislation, in the United States. We
believe that there is a shift in the public’s perception of cannabis from a
state of prohibition to a state of legalization. In October 2018, Canada became
the first major industrialized nation to legalize adult-use cannabis at the
national federal level. Cannabis is still heavily regulated. However, the
medical use of cannabis is now permitted in up to 29 countries and many more
countries have reformed, or are considering reforming, their cannabis uses laws
to include the recreational use of cannabis.

In the 2016 publication by Deloitte, Insights and Opportunities Recreational
Marijuana, the project size of the Canadian adult-use market ranged from CDN$4.9
billion
to CDN$8.7 billion annually. In the 2018 publication by Deloitte, A
Society in Transition, an Industry Ready to Boom, the projected size of the
Canadian adult-use market in 2019 ranged from CDN$1.8 billion to CDN$4.3
billion
. The Canadian medical cannabis industry experienced substantial growth
since 2014. Health Canada projects the Canadian cannabis market will reach
CDN$1.3 billion in annual value by 2024.

We intend to position ourselves with a core emphasis on co-packaging services to
accommodate all consumer-packaged goods required for the sophisticated cannabis
market in Canada and internationally. This will integrate cannabinoid research,
analytical testing, product development and manufacturing.

Our product manufacturing will include, but will not be limited to the
following:



  · Cannabis flower pods for vaporizer use
  · Cannabis extract pods for vaporizer use
  · Cannabis pre-rolls
  · K-Cup infused coffee and tea pods
  · Infused cannabis beverages
  · Infused cannabis edibles
  · Infused topical products and CBD wellness products.




Acquisitions



To take advantage of the opportunity resulting from the legalization of
adult-use cannabis in Canada, we completed several strategic acquisitions and
entered into several significant agreements as follows:



Visava Inc./Canary Rx Inc.

On June 27, 2018, the Company entered into an Agreement and Plan of Share
Exchange (“Exchange Agreement”) with Visava Inc., a private Ontario, Canada
corporation (“Visava”). Visava owns 100% of Canary Rx Inc, (“Canary”), a
Canadian corporation that operates a 44,000 square foot facility located in
Ontario’s Garden Norfolk County for the production of cannabis. Canary is a late
stage Canadian licensed cannabis producer under Health Canada’s Cannabis Act
(“Bill C-45”). Canary expects to produce at least 3,600,000 grams of cannabis
per year, beginning in the third quarter of 2020.

Pursuant to the Exchange Agreement, the Company issued to the Visava
shareholders an aggregate of 25,500,000 shares of the Company’s Common Stock in
exchange for all of the issued and outstanding common stock held by the Visava
shareholders. In addition of its Common Stock, the Company issued to the Visava
shareholders, prorata Common Stock Purchase Warrants to purchase an aggregate of
25,000,000 shares of the Company’s Common Stock at a price per share of $0.10
for a period of two years following the issuance date of the Warrants. The
transactions contemplated by the Exchange Agreement closed effective August 2,
2018
. Visava will continue its business operations as a first-tier wholly-owned
subsidiary of the Company with Canary operating as our second-tier subsidiary.



CannaKorp Inc.

Pursuant to the terms of an Agreement and Plan of Share Exchange dated January
25, 2019
(“Exchange Agreement”), on March 1, 2019 we completed the acquisition
of Massachusetts -based CannaKorp Inc., a Delaware corporation (“CannaKorp”).
CannaKorp has developed a single-use pre-measured pod and vaporizer system for
consumers interested in vaporizing natural herbs, including cannabis. The
patent-pending system is known as The Wisp™ and Wisp Pods™. The Wisp™ vaporizer
system extracts the medically beneficial compounds more efficiently while
simultaneously offering a much safer and enjoyable experience than other
alternatives.

Under the terms of the Exchange Agreement, we issued 30,407,712 shares of our
common stock to the exchanging CannaKorp shareholders in exchange for 99.8% of
the outstanding common stock held by the CannaKorp shareholders. CannaKorp will
continue to operate as our subsidiary.



  6





ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (continued)



Agreements



Serious Seeds B.V.

Effective December 6, 2018, the Company and Canary entered into a Distribution,
Collaboration and Licensing Agreement (“Agreement”) with Serious Seeds B.V.
(“Serious Seeds”), incorporated in the Netherlands, and Simon Smit (“Smit”),
President of Serious Seeds. Under the Agreement, Canary was appointed the
exclusive distributor in Canada and all other legal markets globally of Serious’
proprietary cannabis seed strains and Serious’ cannabis cuttings, dried flowers,
extracts and seeds. In addition, under the Agreement Canary Rx and Serious will
develop certain “Collaborative Products” defined as cannabis seed strains
created collaboratively using Serious’ intellectual property. During the term of
the Agreement, Canary will own all of the intellectual property related to the
Collaborative Products.

Under the Agreement, Smit has granted Canary an exclusive license in Canada and
all legal markets globally to Serious’ intellectual property including the right
to use the service mark of Serious Seeds and all of the names of Serious’
proprietary cannabis seed strains including but not limited to Chronic, AK-47,
White Russian, Bubble Gum, Kali Mist, Warlock, Double Dutch, Biddy, Early,
Motavation and Strawberry-AKeil.

The initial term of the Agreement will be five (5) years and will be
automatically renewed for consecutive five (5) terms subject to rights of
termination upon one hundred and eighty (180) days prior notice. In
consideration of the intellectual property rights granted by Smit to Canary, the
Company will issue to Smit 250,000 shares of the Company’s common stock. In
addition, beginning on the 13th month following the effective date of the
Agreement and continuing through the sixtieth month of the initial term, the
Company will issue to Smit each month 5,208 shares of common stock and warrants
to purchase 200,000 shares of Target common stock at $0.15 per share. In
addition, Smit will be issued warrants in each of the foregoing months to
purchase 16,667 shares of Target common stock at varying exercise prices ranging
from $0.20 to $0.35 per share. All of the warrants must be exercised on or
before the two (2) year anniversary date of each of the warrant issuance dates.

In consideration of Canary Rx’s appointment as Serious’ exclusive distributor in
Canada, Canary Rx will pay Serious certain royalties as follows:



  1st year:                2.00% of gross sales
  2nd year:                2.25% of gross sales
  3rd year:                2.50% of gross sales
  4th year:                2.75% of gross sales
  5th and following years: 3.00% of gross sales



On October 8, 2019, Canary was granted licenses to cultivate, process and sell
cannabis pursuant to the Cannabis Act (Bill C-45). These Standard Licenses
enable Canary to produce approximately 3,600kg of dried cannabis flower per
year. Canary has curated a bank of 3,500 seeds, comprised of more than 125
strains, including the entire Serious Seeds collection. The Company has the
capacity to grow 8 different strains at a time, within the facility’s 8 separate
flower rooms.

Cannavolve Inc. Sales Agency Agreement

Effective December 13, 2018, the Company appointed Cannavolve Inc., an Ontario,
Canada
corporation based in Toronto (Cannavolve”), under the terms of a Licensed
Producer/Licensed Processor Sales Agency Agreement (“Agency Agreement”), as the
Company’s exclusive agent in Canada to market and sell the CannaKorp Wisp™
vaporizer, the Serious Seeds™ products and Canary branded cannabis in the
recreational cannabis markets (collectively the “Products). Cannavolve is an
independent recreational cannabis sales and marketing Company established to
represent licensed producers and licensed processors in Canada of cannabis and
cannabis accessories. Cannavolve operates in Canada with offices in Halifax,
Montreal, Calgary and Vancouver.

Under the Agency Agreement, Cannavolve will be paid a commission of 6% of net
sales based on the wholesale prices of the Products. The initial term of the
Agency Agreement is two (2) years from December 13, 2018 subject to a renewal
term of two (2) additional years. In addition to customary termination
provisions based upon the material default of either the Company or Cannavolve,
we can terminate the Agency Agreement without cause upon ninety (90) days prior
written notice.

cGreen, Inc. Exclusive License Agreement

Effective August 8, 2019, the Company entered into an Exclusive License
Agreement (“License Agreement”) with cGreen, Inc., a Delaware corporation
(“cGreen”). The License Agreement grants to the Company an exclusive license to
manufacture, and distribute the patent-pending THC antidote True Focus™ in the
United States
, Europe and the Caribbean. The term of the license is ten (10)
years and four (4) months from the effective date of August 8, 2019. In
consideration of the license, the Company will issue 10,000,000 shares of its
common stock as follows: (i) 3.500,000 within ten (10) days of the effective
date; (ii) 3,500,000 shares on January 10, 2020; and (iii) 3,000,000 shares not
later than June 10, 2020. In addition, the Company will pay cGreen royalties of
7% of the net sales of the licensed products and 7% of all sublicensing revenues
collected by the Company. The Company will pay cGreen an advance royalty of
$300,000 within ten (10) days of the effective date; $300,000 on January 10,
2020
; and $400,000 on or before June 10, 2020 and $500,000 on or before November
10, 2020
. All advance royalty payments will be credited against the royalties
owed by the Company through December 31, 2020.



  7





ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (continued)

As of the date of the report, the initial payment of royalty payable of $308,140
has been paid during the year ended December 31, 2019 while the remaining in the
amount of $1,191,860 is recorded as royalty payable. No shares have been issued
to date, however, the first tranche of 7,000,000 shares, in the amount of
$520,100, have been recorded in shares to be issued as equity while the
remaining 3,000,000 shares, in the amount of $222,900, are have been recorded in
shares to be issued as liability.

Additionally, the Company is arbitration with cGreen for the above breaches as
per License Agreement.

During the quarter ended December 31, 2019, the intangible asset was written off
based on management’s review and evaluation of its recoverability.

Nabis Holding Sales Agreement

Effective September 17, 2019, CannaKorp entered into a Purchase, Licensing and
Distribution Agreement (“Agreement”) with Nabis Arizona Property LLC of
Scottsdale, Arizona (“Nabis”) concerning the distribution of CannaKorp’s Wisp™
Vaporizer and Wisp™ Pods in Arizona. The term of the Agreement is three (3)
years with automatic renewals for additional one-year periods unless the
Agreement is terminated pursuant to its terms. Nabis is required to pay
CannaKorp $45,000 for the equipment needed to manufacture the WISP™ Pods, of
which $4,500 will be paid within three (3) calendar days of Nabis obtaining
regulatory approval of its vertically integrated license and the balance of
$40,500 within 180 days of the effective date of the Agreement.

Under the Agreement, Nabis is licensed to manufacture the WISP™ Pods and to sell
the WISP™ Pods in conjunction with the sale of the WISP™ Vaporizer. Nabis is
required to meet minimum quarterly orders of two hundred (200) WISP™ Vaporizers
and five thousand (5,000) WISP™ Pods cartridges. Nabis is licensed to sell the
WISP™ Vaporizer and the WISP™ Pods to end users in Arizona, excluding Amazon,
eBay, Walmart or other multistate/national brick and mortar or online sales.
CannaKorp has granted Nabis a right of first refusal to obtain an exclusive
license in Michigan and in Washington for the same rights granted to Nabis in
Arizona.

As of the date of this report, the equipment to Nabis has been shipped and the
CannaKorp has provided Nabis an additional 180 days before invoicing Nabis for
the equipment. Once when the additional 180 day mark has passed, the Company
will invoice Nabis. Additionally, the first quarter of the Nabis agreement
minimums were shipped and invoiced (200 Wisp Units and 5000 Pod Assemblies to
enable Nabis to manufacture 5000 complete Wisp Pods) for online and retail
distribution in the Arizona Market. Nabis has had delays in rolling out all the
products for which they have exclusive licenses with, and the Company expects
their next order will likely be in the next 45 to 60 days.



Joint Venture Agreement


Effective May 14, 2020, Canary entered into a Joint Venture Agreement (“Joint
Venture”) with 9258159 Canada Inc., a corporation organized under the laws of
the Province of Ontario, Canada (referred to as “Thrive Cannabis”) and 2755757
Ontario Inc., a corporation organized under the laws of the Province of Ontario,
Canada
(referred to as “JVCo”). Canary and Thrive Cannabis each hold 50% of the
voting equity interest in JVC. The term of the Joint Venture is five (5) years
from its effective date of May 14, 2020.

Under the Joint Venture, JVCo. is permitted to use a portion, consisting of
seven (7) rooms, of Canary’s licensed cannabis cultivation facilities located in
Simcoe, Ontario, Canada (“Licensed Site Portion”) for the purpose of operating
and managing the Licensed Site Portion for the cultivation and process of
cannabis pursuant to Canary’s license issued by Health Canada. During the term
of the Joint Venture, JVCo. will be responsible for the administration,
operation and management of the Licensed Site Portion and all proceeds from the
sale of the cannabis and related cannabis products cultivated therein will be
payable to the JVCo.



  8





ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (continued)



Employees


As at March 31, 2020, we had one employee Saul Niddam, Chief Innovation Officer,
and also serves as our subsidiary, CannaKorp’s Chief Executive Officer. On
January 9, 2020, Anthony Zarcone was named co-Chief Executive Officer to serve
with Mr. Schindermann. On January 24, 2020, Mr. Schindermann submitted his
resignation as co- Chief Executive Officer; however, he remains a director of
the Company. On February 14, 2020, the Company terminated the employment of
Azmatali Mehrali as Chief Financial Officer. At the present time, the Company
has not appointed a new Chief Financial Officer. Alexander Starr, our former
president, terminated his employment agreement effective February 22, 2019.

We have contracted with a number of independent contractors and consultants to
provide a range of information technology and marketing services who do not
receive cash compensation, but receive shares of our common stock as
compensation. This mitigates any need for full or part-time employees for these
services.

Intellectual Property Protection

Our subsidiary CannaKorp Inc. holds the following patents:

International Patent Application No. PCT/US20115/013778

Title: METHODS AND APPARATUS FOR PRODUCING HERBAL VAPO

Filing Date: January 30, 2015

Ref. No.: B1411.70000WO00


U.S. Provisional Application No.: 61/934.255

Title: CONTAINER POD AND DELIVERY SYSTEM

Filing Date: January 31, 2014

Ref. No.: B1411.70000US00


In addition, CannaKorp has proprietary rights to certain trade names, trademarks
and service marks which include WISP POD™; cPOD™; CANNACUP™; and WISP™.
CannaKorp also has certain proprietary formulas and processes involving herbal
formulas and flavors, proprietary herbal production processes and an herbal base
developed to suspend active ingredients for optimal vaporization.



Results of Operations


We have not generated significant revenue to date and consequently our
operations are subject to all of the risks inherent in the establishment of a
new business enterprise. Our analysis on the performance of the Company is as
follows:

Balance sheet – As at March 31, 2020 and December 31, 2019



Cash


At March 31, 2020 we had cash of $34,675 compared to $10,487 as at December 31,
2019
. The increase is due to funds advance from a related party as a loan during
the current quarter offset by payments of salaries, consulting, professional and
legal expenses during the period.



Prepaid asset


At March 31, 2020 we had prepaid expenses of $60,244 compared to $37,702 as at
December 31, 2019. The balance represents the retainer fees paid to our lawyer,
security deposit for the leased facility and retainer for vendors services.



Sales tax recoverable


At March 31, 2020, we had $54,574 (December 31, 2019: $48,744) of gross sales
tax recoverable. This is due to sales tax paid by the subsidiary on expenses
incurred during the year which are recoverable from the government.

We recorded an allowance of 25% of the sales tax recoverable stemming from the
potential uncollectible balances within the outstanding sales tax recoverable
amount. As of March 31, 2020, the balance of the allowance is $13,642 (December
31, 2019
: $12,186).



  9





ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (continued)

Goodwill and Intangible asset

Goodwill represents the excess of the cost of an acquisition over the fair value
of the Company’s share of the net identifiable assets of our subsidiaries at the
date of acquisition.

In addition, intangible assets represent the Exclusive License Agreement entered
with cGreen. The value of the license is based on 10 million common stock valued
at the market rate of the stock prevailing on August 8, 2019 and the royalty
payments in the amount of $2,243,000. The asset is amortized over the terms of
license i.e. 10 years. During the quarter ended December 31, 2019, the
intangible asset was written off based on our management’s review and evaluation
of the intangible asset’s recoverability.

Fixed assets and capital work in progress

The Company initiated construction on its 44,000 square foot cannabis
cultivation facility in September of 2017. Since then, extensive demolition and
structural upgrades have been carried out at the site. During period ended March
31, 2020
, the Company has capitalized $nil (March 31, 2019: $4,631,006) in
payments to multiple vendors for the construction of the facility.

On May 1, 2019, the Company completed the construction of its 44,000 square foot
cannabis cultivation facility and on May 14, 2019, the Company submitted a Site
Evidence Package to Health Canada as part of the steps to obtain the license to
cultivate cannabis at the Company’s facility. On October 8, 2019, the Company
was granted licenses to cultivate, process and sell cannabis pursuant to
the Cannabis Act (Bill C-45).

Accounts payable and accrued liabilities

Accounts payable amounting to $2,177,479 as at March 31, 2020, primarily
represents consulting and construction services related to capital work in
progress amounting to $806,838, interest on promissory notes and loan amounting
to $79,219, outstanding professional fees amounting to $1,033,087, valuation fee
accrual of $2,500, accounting fee accrual of $3,000 and review fee accrual of
$5,000.

Accounts payable amounting to $2,494,588 as at December 31, 2019, primarily
represents consulting and construction services related to capital work in
progress amounting to $1,079,498, interest on promissory notes and loan
amounting to $53,945, marketing services cost amounting to $18,115, valuation
fee accrual of $3,500, accounting fee accrual of $2,500 and review fee accrual
of $3,000, and outstanding professional fees of $942,000.



Payable to related parties


At March 31, 2020, we had $1,067,371 of amount payable to related parties as
compared to $431,660 as at December 31, 2019. The balance primarily represents a
loan provided by one of the Company’s shareholder, management services fee
outstanding to the managers of the company, and outstanding amount of $40,000 to
be paid to a former shareholder of CannaKorp as part of the settlement
agreement.

For additional details, refer to Note 7 in unaudited condensed consolidated
interim financial statements.



Shareholder advances


Shareholder advances represents expenses paid by the owners from their personal
funds. As at March 31, 2020 and December 31, 2019, there was no outstanding
balance.

Refer to Note 8 for details in the unaudited condensed consolidated interim
financial statements.

Convertible promissory notes payable

We accrued net interest on promissory notes during the quarter ended March 31,
2020
amounting to $10,082 (March 31, 2019: $16,444).

Principal amount outstanding as at March 31, 2020 and December 31, 2019 was
$200,488. As at March 31, 2020, the entire balance was current while as at
December 31, 2019, $32,188 is current portion while $168,300 is the non-current
portion.



  10





ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (continued)

Statement of Operations – For the three months March 31, 2020 and 2019:



Revenue


We generated revenue of $30,000 during March 31, 2020 as compared to $nil
revenue during period ended March 31, 2019. The revenue represents the sale of
Wisp™ vaporizer and pod units.



Expenses


Our expenses are classified primarily into advisory and consultancy fee,
management fees, salaries and wages, legal and professional fees, software
development expense and website development and marketing expense. The
significant decrease in overall expenses for the three months ended March 31,
2020
compared to 2019 is due to lower advisory and consultancy fee, salaries and
wages, and office expenses during the period which resulted due to lower amount
of activity compared to prior period.

Expenses for the three months ended March 31, 2020 primarily represented
consulting fees of $44,269, management fees of $83,239, salary and wages
amounting in total to 138,780, legal and professional charges of $124,000
comprising legal, review, accounting and Edgar agent fee, rent and utilities
amounting to $29,520, office and general expenses amounting to $58,858.

Other income and expenses comprised, change in fair value of derivative
liability amounting to $(3,455,325), loss on settlement of debt amounting to
$nil, interest and bank charges amounting to $36,249, accretion expenses of
$12,200 related to promissory notes and an allowance expense for sales tax
recoverable of $2,624.



  11





ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (continued)

Liquidity and Capital Resources

At March 31, 2020, we had a working capital deficit of $4,844,676 (December 31,
2019
: $4,922,069). We are actively seeking various financing operations to meet
the deficit capital requirements.

To date we have relied on third parties to provide financing for our operations
by way of loans and private placements. The proceeds may not be sufficient to
effectively develop our business to the fullest extent to allow us to maximize
our revenue potential, in which case, we will need additional capital.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to
have a current or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital
expenditures or capital resources that are material to stockholders.



Critical Accounting Policies


Revenue is recognized when persuasive evidence of an arrangement exists,
services have been performed, the amount is fixed and determinable, and
collection is reasonably assured.

Other critical accounting policies are described in the Company’s Form 10-K for
the year ended December 31, 2019.



Subsequent Events


Effective April 20, 2020, the Company issued its promissory note (“Note”) to a
private individual in the principal amount of $236,993. The Note contained an
original issue discount of $15,300 resulting in net proceeds to the Company of
$221,693. The Note carries interest at the rate of 12% per annum. The entire
principal balance plus accrued interest is payable not later than April 20,
2021
. The Note can be prepaid by the Company without prepayment penalty. The net
loan proceeds were used by the Company to satisfy in full an outstanding
institutional debt. The lender is the brother of the Company’s Chief Executive
Officer, Anthony Zarcone, who is also a director of the Company.

During April 2020, the Company and the Company’s shareholder, as mentioned in
Note 7 in the unaudited condensed consolidated interim financial statements,
(“Lender”) entered into a Second Amending Agreement with the Lender pursuant to
which the Lender agreed to lend the Company an additional $70,490 (CAD
$100,000). The new loan carries interest at the rate of 3.0146% per month. The
loan is payable upon demand of the Lender. The remaining terms and conditions of
the Original Loan remain in full force and effect. Effective May 14, 2020, the
Company and the Lender entered into a Third Amending Agreement pursuant to which
the Lender agreed to increase the aggregate loan amount on the Original Loan to
$422,940 (CAD $600,000). The new loan carries interest at the rate of 3.0146%
per month. The loan is payable upon demand of the Lender. The remaining terms
and conditions of the Original Loan remain in full force and effect.

During April 2020, the Company settled with a terminated employee of Canary in
the amount of $6,727 (CAD $9,543). For additional details, refer to Note 13 in
the unaudited condensed consolidated interim financial statements.

During May 2020, pursuant to the amending of Canary’s lease terms, accounts
payable and accrued liabilities in the amount of $694,739 (CAD $985,586) were
forgiven.

Effective May 14, 2020, Canary entered into a Joint Venture Agreement (“Joint
Venture”) with 9258159 Canada Inc., a corporation organized under the laws of
the Province of Ontario, Canada (referred to as “Thrive Cannabis”) and 2755757
Ontario Inc., a corporation organized under the laws of the Province of Ontario,
Canada
(referred to as “JVCo”). Canary and Thrive Cannabis each hold 50% of the
voting equity interest in JVC. The term of the Joint Venture is five (5) years
from its effective date of May 14, 2020.



  12





ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (continued)

Under the Joint Venture, JVCo. is permitted to use a portion, consisting of
seven (7) rooms, of Canary’s licensed cannabis cultivation facilities located in
Simcoe, Ontario, Canada (“Licensed Site Portion”) for the purpose of operating
and managing the Licensed Site Portion for the cultivation and process of
cannabis pursuant to Canary’s license issued by Health Canada. During the term
of the Joint Venture, JVCo. will be responsible for the administration,
operation and management of the Licensed Site Portion and all proceeds from the
sale of the cannabis and related cannabis products cultivated therein will be
payable to the JVCo.

In addition, Canary, Thrive Cannabis, and JVCo. entered into a Unanimous
Shareholder Agreement dated May 14, 2020 governing the management and
administration of the business of JVCo.



Description of Property


We do not own any properties at this time and has no agreements to acquire any
properties.

Our principal executive office is located at 55 Administration Road, Unit 13,
Vaughan, Ontario, Canada, L4K 4G9.

Our subsidiary, Canary, leases a 44,000 square foot facility located in Norfolk
County
, Ontario, Canada to produce medical and recreational cannabis. Our
subsidiary, CannaKorp, leases 1,000 square feet of executive and administrative
office located in a multi-tenant building, located 74 Maple Street, Stoneham,
Massachusetts
, United States of America.

13

© Edgar Online, source Glimpses



Source link Weed Feed

Be the first to comment

Leave a Reply

Your email address will not be published.


*